RYTM
NASDAQ
US
Rhythm Pharmaceuticals, Inc. - Common Stock
$86,29
▼ $-1,83
(-2,08%)
Vol. 546K
6
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$7.1B
ROE
-101,6%
Margine
-110,3%
D/E
36,85
Beta
2,01
52W
$46–$122
Consenso Wall Street
22 analisti · Apr 20268
Acquisto forte
12
Compra
2
Mantieni
0
Vendi
0
Vendita forte
90,9%
Rating Compra
Grafico dei Prezzi
Titoli simili
KYMR
Kymera Therapeutics Inc
$6.1B
ACLX
Arcellx Inc
$3.8B
PTGX
Protagonist Therapeutics Inc
P/E 118,9
$5.5B
SRRK
Scholar Rock Holding Corp
$4.5B
COGT
Cogent Biosciences Inc
$5.4B
CGON
CG Oncology Inc
$3.3B
MIRM
Mirum Pharmaceuticals Inc
$4.1B
PTCT
PTC Therapeutics Inc
P/E 8,1
$6.1B
ERAS
Erasca Inc
$1.1B
Utili
Tasso di battuta: 25,0%| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Dic 2025 | $-0,84 | $-0,73 | +$0,11 |
| Set 2025 | $-0,74 | $-0,82 | $-0,08 |
| Giu 2025 | $-0,69 | $-0,75 | $-0,06 |
| Mar 2025 | $-0,72 | $-0,81 | $-0,09 |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -119.3% | -119.3% | -119.3% | -119.3% | -101.6% | -101.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -96.1% | -117.1% | -117.1% | -117.1% | -110.3% | -110.3% |
| Gross Margin | 88.6% | 89.2% | 89.2% | 89.2% | 89.4% | 89.4% |
| D/E Ratio | 82.19 | 82.19 | 82.19 | 82.19 | 36.85 | 36.85 |
| Current Ratio | 2.79 | 2.79 | 2.79 | 2.79 | 4.75 | 4.75 |
Rapporti chiave
ROA (TTM)
-46,4%
P/S (TTM)
40,98
P/B
20,9
EPS (TTM)
$-3,02
CF/Share
$-3,23
Crescita ricavi 3A
+245,7%
52W High
$122,20
52W Low
$45,91
$45,91
Intervallo 52 settimane
$122,20
Як RYTM виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка RYTM vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
41,0
▲
219%
sopra
peer
(12,9)
vs Peer
vs Settore
Più costoso
P/B
20,9
▲
750%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість RYTM vs аналоги Biotechnology
ROE
-101,6%
▼
51%
sotto
peer
(-67,3%)
vs Peer
vs Settore
Debole
Net margin
-110,3%
▲
62%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
89,4%
▲
14%
sopra
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
-46,4%
▲
1%
sopra
peer
(-46,7%)
vs Peer
vs Settore
In linea
Фінансове здоровʼя RYTM vs аналоги Biotechnology
D/E ratio
36,9
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
4,8
▲
7%
sopra
peer
(4,4)
vs Peer
vs Settore
In linea
Beta
2,0
▲
107%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів RYTM
RYTM
Mediana peer
Industria
RYTM прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio